Tri-Solfen, the anesthetic and antiseptic gel gets the all clear in New Zealand
- By: "Farm Tender" News
- Ag Tech News
- Nov 20, 2017
- 1541 views
- Share
Australian firm Animal Ethics has gained marketing authorization for its Tri-Solfen pain product in New Zealand for sheep and cattle husbandry procedures.
This is the third approval for the product and its first outside of Australia. Animal Ethics is "currently in multiple marketing and distribution rights negotiations" for the New Zealand market.
Tri-Solfen is a local anesthetic and antiseptic gel spray that adheres to wounds and acts as a barrier to environmental stimuli. It also promotes hemostasis and improves wound healing, as it targets the one billion global livestock animals that undergo highly invasive painful husbandry procedures every year.
Tri-Solfen contains two local anesthetics: fast-acting Lignocaine for immediate pain relief; and long-acting Bupivacaine, for prolonged postoperative pain relief. Adrenaline is also included in the formulation for its ability to reduce the shock and stress of blood loss – it also prolongs the anesthetic action.
Additionally, Tri-Solfen contains Cetrimide. This is an antiseptic widely used to cleanse wounds and provide protection from bacterial contamination.
Tri-Solfen's previous approval saw it registered in Australia for sheep and cattle husbandry procedures. In Australia, the product is distributed by Bayer Animal Health. According to Animal Ethics, Tri-Solfen has been used to "successfully treat over 80 million animals undergoing routine surgeries in the Australian livestock industries".
Allan Giffard, managing director of the firm's parent company Medical Ethics, told Animal Pharm registration of Tri-Solfen for pigs in Australia and New Zealand will occur during 2018.
Growing the market coverage
Mr Giffard also told Animal Pharm: "Our next major registrations are on track for Canada, the EU and the US Q1/Q2 of 2019."
Animal Ethics estimates a global market potential of over Aus$350 million ($412 million) per year for Tri-Solfen as a routine treatment on farm procedures in calves, lambs and piglets.
The company is currently expanding the product's commercial horizons. Earlier this year, Animal Ethics was able to boost its plan for Tri-Solfen's global registration following a commercial partnership with Dechra Pharmaceuticals.
Dechra has the global licensing rights (excluding Australia and New Zealand) for the firm's proprietary platform technology in animals. Dechra is supporting Animal Ethics as it targets approvals in the EU and US.
Share Ag News Via